Role of agents other than tumor necrosis factor blockers in the treatment of psoriatic arthritis

Fabiola Atzeni, Luisa Costa, Francesco Caso, Raffaele Scarpa, Piercarlo Sarzi-Puttini

Research output: Contribution to journalArticle

Abstract

Psoriatic arthritis (PsA) is a systemic inflammatory disease characterized by possible peripheral and axial joint involvement, enthesitis, dactylitis, and skin and nail disease. It affects up to one-third of psoriatic patients, and may be associated with comorbidities such as cardiovascular and metabolic diseases. The usually prescribed initial treatment of moderate-severe PsA is methotrexate, which may be accompanied or replaced by a tumor necrosis factor (TNF) inhibitor such as etanercept, infliximab, or adalimumab. However, some patients may become unresponsive (or have contraindications) to available anti-TNF agents and require alternative treatment. The aim of this review is to describe the potential role of some new immunomodulatory agents. The Journal of Rheumatology

Original languageEnglish
Pages (from-to)79-81
Number of pages3
JournalJournal of Rheumatology
Volume93
DOIs
Publication statusPublished - Nov 1 2015

Keywords

  • Apremilast
  • Interleukin-17 inhibitors
  • Psoriatic arthritis
  • Rituximab
  • Tumor necrosis factor inhibitors
  • Ustekinumab

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Role of agents other than tumor necrosis factor blockers in the treatment of psoriatic arthritis'. Together they form a unique fingerprint.

  • Cite this